CJC-1295
CJC-1295 is a long-acting peptide that keeps growth hormone raised for days after one injection. Its human evidence is a small Phase 1 program from 2006 that measured hormone levels, not results people care about.
- Legal lane: not FDA-approved. Not eligible for pharmacy compounding.
- Evidence grade: C
- Form: injection under the skin
- Sport: prohibited
What it is
CJC-1295 is a synthetic version of growth-hormone-releasing hormone. Two different products go by the name:
- With DAC: the original. An added chemical group binds it to a blood protein, giving a half-life of about six to eight days.
- Without DAC (also called modified GRF 1-29): short-acting. This is the form usually paired with ipamorelin, and it is largely unstudied in controlled human trials.
The two are not interchangeable, and labels do not always make clear which one is in the vial.
What the evidence shows
In two placebo-controlled trials in healthy adults published in 2006, a single injection of the DAC form raised average growth hormone two to ten times for six days or more, and raised IGF-1 for nine to eleven days. A follow-up study confirmed the body kept releasing growth hormone in pulses.
That is the whole of the direct human evidence. No trial has shown a benefit for muscle, fat loss, recovery or aging. Development was halted after a death in a later trial that was never linked to the drug.
Legal status
CJC-1295 is not approved and is not on the list of substances pharmacies may compound. An FDA advisory committee recommended against adding it, and it was not part of the October 2026 policy. The FDA has also noted reports of raised heart rate and flushing reactions.
Doses used in studies
No approved dose exists.
The 2006 studies gave single injections of the DAC form sized to body weight, for example 60 or 90 micrograms per kilogram in the follow-up study. These were one-off doses to measure hormone response. Online protocols for the no-DAC form do not come from human trials.